Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder

International Clinical Psychopharmacology

Volumn 20, Issue 4, 2005, Pages 207-212

  Ciliberto, Natalie ^a   Bossie, Cynthia A ^a   Urioste, Ronald ^a   Lasser, Robert A ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

African american; Atypical antipsychotic; Caucasian; Depot; Ethnicity

Indexed keywords

LONG ACTING DRUG; PLACEBO; RISPERIDONE;

ADULT; AFRICAN AMERICAN; AGITATION; ANXIETY DISORDER; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INJECTION PAIN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSONISM; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CONTINENTAL POPULATION GROUPS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 21244496015     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200507000-00003     Document Type: Article

References (28)

1. Adebimpe VR (2004). A second opinion on the use of white norms in psychiatric diagnosis of black patients. Psychiatr Ann 34:543-551.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
3. Ayuso-Gutierrez JL, del Rio Vega JM (1997). Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 28:199-206.
4. Baker FM, Bell CC (1999). Issues in the psychiatric treatment of African Americans. Psychiatr Serv 50:362-368.
5. Chouinard G, Ross-Chouinard A, Annable L, Jones B (1980). Extrapyramidal symptom rating scale. Can J Neurol Sci 7:233.
6. Chung H, Mahler JC, Kakuma T (1995). Racial differences in treatment of psychiatric inpatients. Psychiatr Serv 46:586-591.
7. Csernansky JG, Mahmoud R, Brenner R, for the Risperidone-USA-79 Study Group. (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16-22.
8. Department of Health and Human Services (2004). Mental health: culture, race, and ethnicity: a supplement to mental health: a report of the surgeon general. http://www.surgeongeneral.gov/library/mentalhealth/cre/ (accessed 14 October 2004).
9. Docherty JP, Grogg AL, Kozma C, Lasser R (2002). Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. Poster presented at The American College of Neuropsychopharmacology 41st Annual Meeting, San Juan, Puerto Rico, 8-12 December.
10. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002). Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159:103-108.
11. Emsley RA, Roberts MC, Rataemane S, Pretorius J, Oosthuizen PP, Turner J, et al. (2002). Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry 63:9-14.
12. Frackiewicz EJ, Sramek JJ, Herrera JM, Kurtz NM, Cutler NR (1997). Ethnicity and antipsychotic response. Ann Pharmacother 31:1360-1369.
13. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. (2004). Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161: 692-699.
14. Glazer WM, Morgenstern H, Doucette J (1994). Race and tardive dyskinesia among outpatients at a CMHC. Hosp Commun Psychiatry 45:38-42.
15. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare.
16. Jablensky A (2000). Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 250:274-285.
17. Kane JM (1999). Pharmacologic treatment of schizophrenia. Biol Psychiatry 46:1396-1408.
18. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125-1132.
19. Kaufmann CA, Suarez B, Malaspina D, Pepple J, Svrakic D, Markel PD, et al. (1998). NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet 81: 282-289.
20. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
21. Marder SR, Davis JM, Chouinard G (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538-546.
22. Martinez RA, Berry SA, Lawson WB (2004). Treatment response to risperidone by African American and Caucasian American patients with schizophrenia. Poster presented at the American Psychiatric Association Annual Meeting, New Orleans, LA, 5-10 May.
23. Opolka JL, Rascati KL, Brown CM, Gibson PJ (2003). Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother 37: 625-630.
24. Poolsup N, Li Wan Po A, Knight TL (2000). Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 25:197-220.
25. Ruiz P (2004). Addressing culture, race and ethnicity in psychiatric practice. Psychiatr Ann 34:527-532.
26. Strakowski SM, Shelton RC, Kolbrener ML (1993). The effects of race and comorbidity on clinical diagnosis in patients with psychosis. J Clin Psychiatry 54:96-102.
27. Strakowski SM, McElroy SL, Keck PE Jr, West SA (1996). Racial influence on diagnosis in psychotic mania. J Affect Disord 39:157-162.
28. Weiden PJ, Kozma C, Grogg A, Locklear J (2004). Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55:886-891.